低分易中的免疫学二区SCI杂志

分类：SCI期刊 时间：2023-12-18 10:57 关注：(1)

　　低分易中的免疫学二区SCI期刊有哪些呢？SCI期刊是有分区划分的，根据影响因子的高低划分为四个分区，分别是一区、二区、三区以及四区，分区越靠前说明期刊的影响力越高。发表SCI论文之前要选择相关的期刊投稿，接下来，详细的推荐几本期刊，仅供参考。

　　1、JOURNAL OF IMMUNOLOGY

　　学科领域：

　　大类：医学

　　小类：免疫学

　　中科院分区：2区

　　影响因子：4.4

　　期刊简介：The JI publishes novel, peer-reviewed findings in all areas of experimental immunology, including innate and adaptive immunity, inflammation, host defense, clinical immunology, autoimmunity and more. Special sections include Cutting Edge articles, Brief Reviews and Pillars of Immunology. The JI is published by The American Association of Immunologists (AAI)

　　JI 在实验免疫学的所有领域发表经过同行评审的新颖发现，包括先天性和适应性免疫、炎症、宿主防御、临床免疫学、自身免疫等。特别版块包括前沿文章、简要评论和免疫学支柱。JI 由美国免疫学家协会 (AAI) 出版

　　2、INFLAMMOPHARMACOLOGY

　　学科领域：

　　大类：医学

　　小类：免疫学

　　中科院分区：2区

　　影响因子：5.8

　　期刊简介：Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas

　　《炎症药理学》是国际基础与临床药理学联合会 (IUPHAR) 胃肠道分会和匈牙利实验与临床药理学会 (HECPS) 的官方出版物。Inflammopharmacology 发表有关炎症及其药理学控制各个方面的论文，强调比较 (a) 不同的炎症状态，以及 (b) 用于治疗炎症状况的药物的作用、治疗功效和安全性。炎症病症类型的比较方面包括胃肠道疾病（例如溃疡性结肠炎、克罗恩病）、寄生虫病、药物和环境因素作用的毒理学表现、关节炎病症以及骨骼肌损伤或老化的炎症影响。该期刊有七个主要兴趣领域

　　3、OncoImmunology

　　学科领域：

　　大类：医学

　　小类：免疫学

　　中科院分区：2区

　　影响因子：5.8

　　期刊简介：Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.

　　肿瘤免疫学涉及癌症的自然或治疗诱导的识别，以及肿瘤发生、炎症和免疫监视之间复杂的相互作用。我们现在创建了一本新的、备受瞩目的期刊《OncoImmunology》，专门研究肿瘤免疫学。最近的进展使得抗癌免疫疗法首次进行临床论证（并获得 FDA 批准）。人们越来越怀疑，出乎意料的是，目前使用的许多化疗药物的功效取决于免疫效应物的主动贡献。用一个激烈的比喻来说，应用成功的化疗（或放疗）方案的肿瘤学家利用了免疫系统识别肿瘤特异性或肿瘤相关抗原并控制癌细胞（干细胞）生长的能力，而没有意识到无形的因素。伸出援助之手。因此，免疫生物标志物对于确定癌症预后和预防癌症变得越来越重要。